Skip to main content
search

Alzheimer’s prevention clinical trial discontinued

By July 12, 2019Commentary, In the News

Contributed by Joshua Grill, PhD

The field of Alzheimer’s disease drug development received more troubling news yesterday, when the leaders of the GENERATION program halted their prevention clinical trials of a drug aiming to prevent the formation of the beta amyloid protein in people at risk to get Alzheimer’s disease.

The GENERATION program is led by investigators at Banner Alzheimer’s Institute and is an important study in people at increased genetic risk to someday develop Alzheimer’s disease, based on the apolipoprotein E (APOE) gene. The trials were stopped because preliminary results indicated that the drug under study, CNP520 (being developed by Novartis and Amgen), worsened cognition. CNP520 is a BACE (beta-site amyloid precursor protein cleavage enzyme) Inhibitor. BACE Inhibitors can reduce amyloid levels substantially, but CNP520 now joins several other candidate BACE Inhibitors found to worsen cognitive performance.

Click here to read the press release >

Related posts:

  1. FDA delays decision on donanemab The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab...
  2. FDA Advisory Panel meeting held to consider potential approval of donanemab Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND....
  3. AlzForum provides update on MODEL-AD at UCI AlzForum, the popular online publication for Alzheimer’s researchers, published a summary of recent advances from the MODEL-AD teams and highlighted the work of the principal investigators at UCI, Drs. Kim Green, Andrea Tenner, and Frank LaFerla.  The article also called attention to innovative research in the Green Lab, including work...
Close Menu